Publicacións en colaboración con investigadores/as de Hospital Universitario de Salamanca (23)

2024

  1. Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO Group

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 17, pp. 3704-3714

  2. Liquid biopsy for molecular characterization of diffuse large B-cell lymphoma and early assessment of minimal residual disease

    British Journal of Haematology, Vol. 205, Núm. 1, pp. 109-121

  3. Rationale and design of RESILIENCE: A prospective randomized clinical trial evaluating remote ischaemic conditioning for the prevention of anthracycline cardiotoxicity

    European Journal of Heart Failure, Vol. 26, Núm. 10, pp. 2213-2222

  4. Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 14, pp. 1612-1618

2022

  1. Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 3, pp. 242-251

2021

  1. R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group

    Cancer Medicine, Vol. 10, Núm. 4, pp. 1314-1326

2020

  1. Results of an early access treatment protocol of daratumumab monotherapy in spanish patients with relapsed or refractory multiple myeloma

    HemaSphere, Vol. 4, Núm. 3

2018

  1. A new prognostic model identifies patients aged 80 years and older with diffuse large B-cell lymphoma who may benefit from curative treatment: A multicenter, retrospective analysis by the Spanish GELTAMO group

    American Journal of Hematology, Vol. 93, Núm. 7, pp. 867-873

  2. Polymorphisms in receptors involved in opsonic and nonopsonic phagocytosis, and correlation with risk of infection in oncohematology patients

    Infection and Immunity, Vol. 86, Núm. 12

2017

  1. Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice

    International Journal of Hematology, Vol. 106, Núm. 4, pp. 508-516

  2. The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy*

    Leukemia and Lymphoma, Vol. 58, Núm. 5, pp. 1144-1152

2016

  1. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice

    European Journal of Haematology, Vol. 97, Núm. 3, pp. 297-302

2015

  1. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia

    American Journal of Hematology, Vol. 90, Núm. 3, pp. E40-E43

2014

  1. Genomic analysis of clonal eosinophils by CGH arrays reveals new genetic regions involved in chronic eosinophilia

    European Journal of Haematology, Vol. 93, Núm. 5, pp. 422-428

2012

  1. Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement

    European Journal of Haematology, Vol. 89, Núm. 1, pp. 37-41

2010

  1. Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients

    Haematologica, Vol. 95, Núm. 5, pp. 745-751

2009

  1. High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics

    Leukemia Research, Vol. 33, Núm. 12, pp. 1706-1709

  2. Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide

    Leukemia and Lymphoma, Vol. 50, Núm. 8, pp. 1283-1289

  3. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia

    Blood, Vol. 114, Núm. 1, pp. 148-152

2008

  1. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia

    Haematologica, Vol. 93, Núm. 12, pp. 1797-1805